AstraZeneca PLC 6-K Report: Key Insights on Voting Rights & Share Capital (Nov 2025)

Here are the key insights extracted from the provided financial report (Form 6-K) for AstraZeneca PLC:

Company Overview:

• Company Name: AstraZeneca PLC
• Location: Cambridge Biomedical Campus, Cambridge, United Kingdom
• Business Focus: Global biopharmaceutical company specializing in the discovery, development, and commercialization of prescription medicines, particularly in Oncology, Rare Diseases, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Reporting Details:

• Filing Date: November 3, 2025
• Commission File Number: 001-11960
• Form Submitted: 6-K

Voting Rights and Share Capital:

• Total Voting Rights: As of October 31, 2025, AstraZeneca PLC has a total of 1,550,712,906 ordinary shares with voting rights, representing an issued share capital of US$0.25 per share.
• Treasury Shares: No shares are held in Treasury.
• Usage of Voting Rights Figure: This figure can be used by shareholders to determine if they need to notify changes in their interests in AstraZeneca PLC under UK Financial Conduct Authority's Disclosure and Transparency Rules.

Compliance:

• The report is submitted in compliance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.

Company Contacts:

• Company Secretary: Matthew Bowden
• Direct inquiries can be made through investor relations or media contacts as indicated in the report.

Additional Notes:

• AstraZeneca's innovative medicines are sold in over 125 countries, reaching millions of patients globally.
• The company is publicly traded on major stock exchanges including LSE, STO, and Nasdaq under the ticker AZN.

This report is crucial for investors as it provides essential information regarding the voting structure and share capital of AstraZeneca, allowing for informed decisions regarding shareholder notifications and other related governance matters.